Cogent Biosciences, Inc. Contract Liability (Deferred Revenue)
Cogent Biosciences, Inc. (COGT) had Contract Liability (Deferred Revenue) of $312.00 thousand as of 2020-06-30, per its 10-Q filed 2020-08-11.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current › Deferred Revenue, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2021-03-16
- 2020-06-30: Contract with Customer, Liability, Current $312.00K.
- 2020-03-31: Contract with Customer, Liability, Current $841.00K.
- 2019-12-31: Contract with Customer, Liability, Current $1.31M.
- 2019-09-30: Contract with Customer, Liability, Current $14.72M.
| Period end | Contract with Customer, Liability, Current |
|---|---|
| 2020-06-30 | $312.00K 10-Q · filed 2020-08-11 |
| 2020-03-31 | $841.00K 10-Q · filed 2020-05-11 |
| 2019-12-31 | $1.31M 10-K · filed 2021-03-16 |
| 2019-09-30 | $14.72M 10-Q · filed 2019-11-12 |
| 2019-06-30 | $15.18M 10-Q · filed 2019-08-12 |
| 2019-03-31 | $16.93M 10-Q · filed 2019-05-13 |
| 2018-12-31 | $17.95M 10-K · filed 2020-03-26 |
| 2017-12-31 | $6.89M 10-K · filed 2019-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |